Colin A. Flaveny, Ph.D.
Affiliations: | 2010 | Pennsylvania State University, State College, PA, United States |
Area:
Molecular Biology, ToxicologyGoogle:
"Colin Flaveny"Parents
Sign in to add mentor| Gary H. Perdew | grad student | 2010 | Penn State | |
| (Molecular and species-specific determinants of aryl hydrocarbon receptor transcriptional activity.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Burris TP, de Vera IMS, Cote I, et al. (2023) . Pharmacological Reviews |
| Musicant AM, Parag-Sharma K, Gong W, et al. (2021) CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition. Cell Reports. 34: 108768 |
| Welch RD, Billon C, Kameric A, et al. (2020) Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice. Plos One. 15: e0227720 |
| Carpenter KJ, Valfort AC, Steinauer N, et al. (2019) LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer. Scientific Reports. 9: 19530 |
| Sur S, Nakanishi H, Flaveny C, et al. (2019) Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract. Cell Communication and Signaling : Ccs. 17: 131 |
| Musicant AM, Sharma KP, Henry EC, et al. (2019) Abstract 874: The CRTC1/MAML2 oncogene induces a PGC-1a splice variant that sensitizes mucoepidermoid carcinoma cells to PPARg inhibition Cancer Research. 79: 874-874 |
| May A, Abuirqeba S, Hamilton Z, et al. (2018) MP70-14 REGULATION OF PROSTATE CANCER METABOLISM AND INVASIVENESS BY THE LIVER X RECEPTOR Journal of Urology. 199 |
| Welch RD, Billon C, Valfort AC, et al. (2017) Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle. Scientific Reports. 7: 17142 |
| Welch RD, Flaveny CA. (2017) REV-ERB and ROR: therapeutic targets for treating myopathies. Physical Biology. 14: 045002 |
| Flaveny CA, Griffett K, El-Gendy Bel-D, et al. (2015) Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell. 28: 42-56 |